Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hermansen, M. N.
Right arrow Articles by Bisgaard, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hermansen, M. N.
Right arrow Articles by Bisgaard, H.
(Chest. 2006;129:1203-1209.)
© 2006 American College of Chest Physicians

Acute Relief of Exercise-Induced Bronchoconstriction by Inhaled Formoterol in Children With Persistent Asthma*

Mette Northman Hermansen, MD; Kim Gjerum Nielsen, MD; Frederik Buchvald, MD, PhD; Jakob Jessing Jespersen, MD; Thomas Bengtsson, MSc and Hans Bisgaard, MD, DMSci

* From the Department of Pediatrics (Drs. Hermansen, Nielsen, Buchvald, Jespersen, and Bisgaard), Danish Pediatric Asthma Center, Copenhagen University Hospital, Hellerup, Denmark; and Clinical Science (Mr. Bengtsson), AstraZeneca R&D Lund, Lund, Sweden.

Correspondence to: Hans Bisgaard, MD, Department of Pediatrics, Copenhagen University Hospital, Gentofte, Niels Andersens Vej 65, DK-2900 Hellerup, Denmark; e-mail: Bisgaard{at}copsac.dk

Abstract

Study objective: To compare the acute bronchodilatory effect of the long-acting ß2-agonist formoterol against the short-acting ß2-agonist (SABA) terbutaline during exercise-induced bronchoconstriction (EIB) in children with asthma.

Design: A randomized, double-blind, placebo-controlled, crossover study of the immediate effect of formoterol, 9 µg, vs terbutaline, 0.5 mg, and placebo administered as dry powder at different study days. Exercise challenge test was used as a model of acute bronchoconstriction.

Patients: Twenty-four 7- to 15-year-old children with persistent asthma.

Interventions: The children performed standardized treadmill exercise tests, breathing dry air, with a submaximal workload. Study medication was administered 5 min after exercise if FEV1 dropped ≥ 15% within 5 min after exercise. FEV1 and forced expiratory flows were measured repeatedly until 60 min after dose.

Results: Formoterol and terbutaline offered a significant acute bronchodilatory effect from 3 min after dose compared with placebo (p < 0.001). There was no difference between formoterol and terbutaline in FEV1 5 min after dose (p = 0.15), with a mean increase from each predrug baseline of 62% of the maximum increase for both. Median times to recovery within 5% of baseline FEV1 were 5.0 min and 7.4 min for formoterol and terbutaline, respectively (p = 0.33).

Conclusion: Single-dose formoterol, 9 µg, via dry powder inhaler provided an acute bronchodilatory effect similar to terbutaline during EIB in schoolchildren with persistent asthma. Formoterol is at least as effective as SABA and may be considered an alternative in the treatment of acute bronchoconstriction in school children.

Key Words: asthma, exercise-induced • bronchodilators • children






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American College of Chest Physicians.